What to watch. AstraZeneca gets nod to launch cancer drug

AstraZeneca Pharma India has received approval from the Drug Controller General of India to market Durvalumab, a cancer treatment medicine. The nod paves the way for it to launch the product in the country. Durvalumab is indicated as a treatment option for patients with locally-advanced, unresectable non-small cell lung cancer and metastatic urothelial carcinoma. Shareholders will closely monitor the development.